{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:53:07Z","timestamp":1792842787206,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.biopsych.2013.07.031","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T22:00:21Z","timestamp":1378418421000},"page":"520-526","source":"Crossref","is-referenced-by-count":27,"title":["Progress Update: Fluid and Imaging Biomarkers in Alzheimer\u2019s Disease"],"prefix":"10.1016","volume":"75","author":[{"given":"Courtney L.","family":"Sutphen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2013.07.031_bib1","series-title":"Dementia: A Public Health Priority","year":"2012"},{"key":"10.1016\/j.biopsych.2013.07.031_bib2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archneur.58.9.1395","article-title":"Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease","volume":"58","author":"Price","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: A practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"ACTA Neuropathol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2377-12-72","article-title":"Diagnostic and economic evaluation of new biomarkers for Alzheimer\u2019s disease: The research protocol of a prospective cohort study","volume":"12","author":"Handels","year":"2012","journal-title":"BMC Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib5","doi-asserted-by":"crossref","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","article-title":"Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer\u2019s disease","volume":"6","author":"Perrin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2013.07.031_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2013.07.031_bib7","unstructured":"Eli Lilly and Company (2012): Lilly announces detailed results of the Phase III solanezumab EXPEDITION studies following a presentation of the independent analyses by the Alzheimer\u2019s disease cooperative study (ADCS) [press release]. Available at: http:\/\/newsroom.lilly.com\/releasedetail.cfm?ReleaseID=711933. Accessed August 12, 2013."},{"key":"10.1016\/j.biopsych.2013.07.031_bib8","unstructured":"Pfizer Inc (2012): Pfizer announces co-primary clinical endpoints not met in second phase III bapineuzumab study in mild-to-moderate Alzheimer\u2019s disease patients who do not carry the Apoe4 genotype [press release]. Available at: http:\/\/www.businesswire.com\/news\/home\/20120806006130\/en\/Pfizer-Announces-Co-Primary-Clinical-Endpoints-Met-Phase. Accessed August 12, 2013."},{"key":"10.1016\/j.biopsych.2013.07.031_bib9","unstructured":"Eli Lilly and Company (2012): Lilly provides update on next steps for solanezumab [press release]. Available at: http:\/\/newsroom.lilly.com\/releasedetail.cfm?releaseid=726309. Accessed August 12, 2013."},{"key":"10.1016\/j.biopsych.2013.07.031_bib10","first-page":"221","article-title":"Low frequency of post-lumbar puncture headache in demented patients","volume":"88","author":"Blennow","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.biopsych.2013.07.031_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2174\/156720509788486509","article-title":"Safety of lumbar puncture procedures in patients with Alzheimer\u2019s disease","volume":"6","author":"Peskind","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.biopsych.2013.07.031_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF A\u03b2 42 levels correlate with amyloid-neuropathology in a population-based autopsy study","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","article-title":"Beta amyloid in Alzheimer\u2019s disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid","volume":"65","author":"Grimmer","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.07.031_bib16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","article-title":"Relationships between biomarkers in aging and dementia","volume":"73","author":"Jagust","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","article-title":"Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain","volume":"66","author":"Tapiola","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/156720510790274446","article-title":"High PIB retention in Alzheimer\u2019s disease is an early event with complex relationship with CSF biomarkers and functional parameters","volume":"7","author":"Forsberg","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.biopsych.2013.07.031_bib19","doi-asserted-by":"crossref","first-page":"15861","DOI":"10.1523\/JNEUROSCI.3272-11.2011","article-title":"Dynamic analysis of amyloid \u03b2-protein in behaving mice reveals opposing changes in ISF versus parenchymal A\u03b2 during age-related plaque formation","volume":"31","author":"Hong","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.07.031_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2013.07.031_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/archneurol.2009.55","article-title":"Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type","volume":"66","author":"Snider","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jalz.2012.08.001","article-title":"Advancing Alzheimer\u2019s disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit","volume":"8","author":"Naylor","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2013.07.031_bib24","first-page":"325","article-title":"Biomarkers of Alzheimer disease: Current and future applications to diagnostic criteria","volume":"19","author":"Sperling","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.biopsych.2013.07.031_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2013.07.031_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/17520363.2.4.363","article-title":"Tau as a biomarker of neurodegenerative diseases","volume":"2","author":"Schraen-Maschke","year":"2008","journal-title":"Biomark Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib27","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2013.07.031_bib28","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1523\/JNEUROSCI.2569-11.2011","article-title":"In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice","volume":"31","author":"Yamada","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.07.031_bib29","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","article-title":"Trans-cellular propagation of tau aggregation by fibrillar species","volume":"287","author":"Kfoury","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopsych.2013.07.031_bib30","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000216841","article-title":"Rapid progression from mild cognitive impairment to Alzheimer\u2019s disease in subjects with elevated levels of tau in cerebrospinal fluid and the Apoe \u03b54\/\u03b54 genotype","volume":"27","author":"Blom","year":"2009","journal-title":"Dement Geriatr Cogn"},{"key":"10.1016\/j.biopsych.2013.07.031_bib31","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.63.6.1144","article-title":"CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects","volume":"63","author":"Buerger","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","article-title":"The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers","volume":"7","author":"Mattsson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2013.07.031_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2013.07.031_bib34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","article-title":"Age-dependent changes in brain, CSF, and plasma amyloid \u03b2 protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease","volume":"21","author":"Kawarabayashi","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.07.031_bib35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","article-title":"The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients","volume":"54","author":"Lee","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.biopsych.2013.07.031_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.22448","article-title":"Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease","volume":"70","author":"Tarawneh","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1212\/WNL.0b013e318248e568","article-title":"CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease","volume":"78","author":"Tarawneh","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/CDLI.9.3.598-604.2002","article-title":"YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis","volume":"9","author":"\u00d8stergaard","year":"2002","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease","volume":"68","author":"Craig-Schapiro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.07.031_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","article-title":"Cerebrospinal fluid microglial markers in Alzheimer\u2019s disease: Elevated chitotriosidase activity but lack of diagnostic utility","volume":"13","author":"Mattsson","year":"2011","journal-title":"Neuromol Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/bmm.12.42","article-title":"Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease","volume":"6","author":"Fagan","year":"2012","journal-title":"Biomark Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/bmm.09.89","article-title":"Biomarkers of oxidative damage and inflammation in Alzheimer\u2019s disease","volume":"4","author":"Galasko","year":"2010","journal-title":"Biomark Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib44","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.neurobiolaging.2011.05.013","article-title":"Serial CSF sampling in Alzheimer\u2019s disease: Specific versus non-specific markers","volume":"33","author":"Kester","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2013.07.031_bib45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ana.10618","article-title":"Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia","volume":"54","author":"Han","year":"2003","journal-title":"Ann Neurol"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2013.07.031_bib46","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.neurobiolaging.2011.09.004","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Plasma A\u03b240 and A\u03b242, and genetic variants","volume":"32","author":"Mayeux","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2013.07.031_bib47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","article-title":"Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer\u2019s disease","volume":"1","author":"Fagan","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib48","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000017187","article-title":"Tau immunoreactivity detected in human plasma, but no obvious increase in dementia","volume":"10","author":"Ingelson","year":"1999","journal-title":"Dement Geriatr Cogn"},{"key":"10.1016\/j.biopsych.2013.07.031_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer\u2019s disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.biopsych.2013.07.031_bib50","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1371\/journal.pone.0028092","article-title":"A blood-based screening tool for Alzheimer\u2019s disease that spans serum and plasma: Findings from TARC and ADNI","volume":"6","author":"O\u2019Bryant","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2013.07.031_bib51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cell.2010.11.054","article-title":"Identification of candidate IgG biomarkers for Alzheimer\u2019s disease via combinatorial library screening","volume":"144","author":"Reddy","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopsych.2013.07.031_bib52","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jalz.2011.09.172","article-title":"The Alzheimer\u2019s Disease Neuroimaging Initiative: A review of papers published since its inception","volume":"8","author":"Weiner","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2013.07.031_bib53","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/brain\/119.6.2001","article-title":"Presymptomatic hippocampal atrophy in Alzheimer\u2019s disease. A longitudinal MRI study","volume":"119","author":"Fox","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2013.07.031_bib54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(05)74869-8","article-title":"MRI of entorhinal cortex in mild Alzheimer\u2019s disease","volume":"353","author":"Bobinski","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2013.07.031_bib55","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1212\/WNL.52.7.1397","article-title":"Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment","volume":"52","author":"Jack","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib56","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1212\/WNL.49.3.786","article-title":"Medial temporal atrophy on MRI in normal aging and very mild Alzheimer\u2019s disease","volume":"49","author":"Clifford","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib57","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1212\/WNL.55.11.1636","article-title":"Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type","volume":"55","author":"Csernansky","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib58","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1212\/WNL.52.8.1687","article-title":"Correlation between rates of brain atrophy and cognitive decline in AD","volume":"52","author":"Fox","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib59","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change","volume":"73","author":"Vemuri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib60","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1073\/pnas.98.2.676","article-title":"A default mode of brain function","volume":"98","author":"Raichle","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.biopsych.2013.07.031_bib61","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1212\/01.wnl.0000171450.97464.49","article-title":"Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD","volume":"65","author":"Dickerson","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib62","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.neuroimage.2005.12.033","article-title":"Changes in hippocampal connectivity in the early stages of Alzheimer\u2019s disease: Evidence from resting state fMRI","volume":"31","author":"Wang","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2013.07.031_bib63","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.neurobiolaging.2011.06.007","article-title":"Resting state fMRI in Alzheimer\u2019s disease: Beyond the default mode network","volume":"33","author":"Agosta","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2013.07.031_bib64","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1073\/pnas.0308627101","article-title":"Default-mode network activity distinguishes Alzheimer\u2019s disease from healthy aging: Evidence from functional MRI","volume":"101","author":"Greicius","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.biopsych.2013.07.031_bib65","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2013.07.031_bib66","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1523\/JNEUROSCI.5698-11.2012","article-title":"Loss of intranetwork and internetwork resting state functional connections with Alzheimer\u2019s disease progression","volume":"32","author":"Brier","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.07.031_bib67","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1148\/radiol.10091402","article-title":"Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease","volume":"256","author":"Karow","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib68","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1212\/WNL.0b013e31823a0ef7","article-title":"Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease","volume":"77","author":"Chen","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib70","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib71","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography \u03b2-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib72","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/WCO.0b013e3283168e1a","article-title":"The future of amyloid-beta imaging: A tale of radionuclides and tracer proliferation","volume":"21","author":"Klunk","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib73","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging \u03b2-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2013.07.031_bib74","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: Implications for sequence of pathological events in Alzheimer\u2019s disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2013.07.031_bib75","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease","volume":"66","author":"Morris","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib76","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","article-title":"Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study","volume":"73","author":"Okello","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib77","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2174\/1568026611313080004","article-title":"Fluorine-18 radiolabeled heterocycles as PET tracers for imaging \u03b2-amyloid plaques in Alzheimer\u2019s disease","volume":"13","author":"Zeng","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.biopsych.2013.07.031_bib78","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/03610918.2012.661906","article-title":"Youden index and associated cutoff points for three ordinal diagnostic groups","volume":"42","author":"Luo","year":"2012","journal-title":"Commun Stat Simulat"},{"key":"10.1016\/j.biopsych.2013.07.031_bib79","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0272989X04271046","article-title":"Combining correlated diagnostic tests: Application to neuropathologic diagnosis of Alzheimer\u2019s disease","volume":"24","author":"Xiong","year":"2004","journal-title":"Med Decis Making"},{"key":"10.1016\/j.biopsych.2013.07.031_bib80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/biostatistics\/1.2.123","article-title":"Combining diagnostic test results to increase accuracy","volume":"1","author":"Pepe","year":"2000","journal-title":"Biostatistics"},{"key":"10.1016\/j.biopsych.2013.07.031_bib81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Roy Stat Soc B Met"},{"key":"10.1016\/j.biopsych.2013.07.031_bib82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1191\/0962280202sm279ra","article-title":"Inference for multi-state models from interval-censored data","volume":"11","author":"Commenges","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.biopsych.2013.07.031_bib83","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: A follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib84","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/01.wnl.0000267428.62582.aa","article-title":"CSF tau\/A\u03b242 ratio for increased risk of mild cognitive impairment: A follow-up study","volume":"69","author":"Li","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib85","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archneurol.2011.105","article-title":"Comparison of analytical platforms for cerebrospinal fluid measures of \u03b2-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology","volume":"68","author":"Fagan","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib86","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or Parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib87","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib88","doi-asserted-by":"crossref","first-page":"e29868","DOI":"10.1371\/journal.pone.0029868","article-title":"Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer\u2019s disease","volume":"7","author":"Bj\u00f6rkqvist","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2013.07.031_bib89","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/WNL.0b013e318266fa70","article-title":"Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease","volume":"79","author":"Hu","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib90","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/archneurol.2012.1070","article-title":"Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease","volume":"69","author":"Soares","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.07.031_bib91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neuroimage.2012.04.056","article-title":"Combining MRI and CSF measures for classification of Alzheimer\u2019s disease and prediction of mild cognitive impairment conversion","volume":"62","author":"Westman","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2013.07.031_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt59","article-title":"Autosomal-dominant Alzheimer\u2019s disease: A review and proposal for the prevention of Alzheimer\u2019s disease","volume":"3","author":"Bateman","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.biopsych.2013.07.031_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-2011-0059","article-title":"Alzheimer\u2019s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments","volume":"26","author":"Reiman","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.biopsych.2013.07.031_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.biopsych.2013.07.031_bib95","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/gps.2496","article-title":"The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson\u2019s disease dementia","volume":"26","author":"Andersson","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.biopsych.2013.07.031_bib96","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1755-5949.2012.00311.x","article-title":"Cerebrospinal fluid biomarkers in Alzheimer\u2019s disease and geriatric depression: Preliminary findings from Brazil","volume":"18","author":"Reis","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.biopsych.2013.07.031_bib97","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1176\/appi.ajp.160.2.376","article-title":"Differentiation of geriatric major depression from Alzheimer\u2019s disease with CSF tau protein phosphorylated at threonine 231","volume":"160","author":"Buerger","year":"2003","journal-title":"Am J Psychiat"},{"key":"10.1016\/j.biopsych.2013.07.031_bib98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","article-title":"Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort","volume":"78","author":"Schoonenboom","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2013.07.031_bib99","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3233\/JAD-1999-1606","article-title":"Decreased levels of amyloid-\u03b2 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients","volume":"1","author":"Van Everbroeck","year":"1999","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.biopsych.2013.07.031_bib100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0304-3940(97)00215-2","article-title":"Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"225","author":"Otto","year":"1997","journal-title":"Neurosci Lett"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322313007142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322313007142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:18:49Z","timestamp":1715966329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322313007142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0006322313007142"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2013.07.031","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}